Fosun Wanbang Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FOSUN WANBANG
FOSUN WANBANG has four approved drugs.
There are three tentative approvals on FOSUN WANBANG drugs.
Summary for Fosun Wanbang
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Fosun Wanbang
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fosun Wanbang | SUNITINIB MALATE | sunitinib malate | CAPSULE;ORAL | 218012-002 | Aug 21, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fosun Wanbang | LEFLUNOMIDE | leflunomide | TABLET;ORAL | 077087-002 | Sep 13, 2005 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fosun Wanbang | GUANFACINE HYDROCHLORIDE | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 217638-002 | Jun 12, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fosun Wanbang | MYCOPHENOLATE SODIUM | mycophenolate sodium | TABLET, DELAYED RELEASE;ORAL | 216637-001 | May 29, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
